Potential of hybrid 18F-fluorocholine PET/MRI for prostate cancer imaging by de Perrot, Thomas et al.
ORIGINAL ARTICLE
Potential of hybrid 18F-fluorocholine PET/MRI for prostate
cancer imaging
Thomas de Perrot & Olivier Rager & Max Scheffler &
Martin Lord & Marc Pusztaszeri & Christophe Iselin &
Osman Ratib & Jean-Paul Vallee
Received: 9 January 2014 /Accepted: 15 April 2014 /Published online: 20 May 2014
# Springer-Verlag Berlin Heidelberg 2014
Abstract
Purpose To report the first results of hybrid 18F-fluorocholine
PET/MRI imaging for the detection of prostate cancer.
Methods This analysis included 26 consecutive patients
scheduled for prostate PET/MRI before radical prostatectomy.
The examinations were performed on a hybrid whole-body
PET/MRI scanner. The MR acquisitions which included T2-
weighted, diffusion-weighted and dynamic contrast-enhanced
sequences were followed during the same session by whole-
body PET scans. Parametric maps were constructed to mea-
sure normalized T2-weighted intensity (nT2), apparent diffu-
sion coefficient (ADC), volume transfer constant (Ktrans), ex-
travascular extracellular volume fraction (ve) and standardized
uptake values (SUV). With pathology as the gold standard,
ROC curves were calculated using logistic regression for each
parameter and for the best combination with and without PET
to obtain a MR model versus a PETMR model.
Results Of the 26 patients initially selected, 3 were excluded
due to absence of an endorectal coil (2 patients) or prosthesis
artefacts (1 patient). In the whole prostate, the area under the
curve (AUC) for SUVmax, ADC, nT2, K
trans and ve were
0.762, 0.756, 0.685, 0.611 and 0.529 with a best threshold at
3.044 for SUVmax and 1.075 × 10
−3 mm2/s for ADC. The
anatomical distinction between the transition zone and the
peripheral zone showed the potential of the adjunctive use of
PET. In the peripheral zone, the AUC of 0.893 for the PETMR
model was significantly greater (p=0.0402) than the AUC of
0.84 for theMRmodel only. In the whole prostate, no relevant
correlation was observed between ADC and SUVmax. The
SUVmax was not affected by the Gleason score.
Conclusion The performance of a hybrid whole-body 18F-
fluorocholine PET/MRI scan in the same session combined
with a prostatic MR examination did not interfere with the
diagnostic accuracy of the MR sequences. The registration of
the PET data and the T2 anatomical MR sequence data
allowed precise localization of hypermetabolic foci in the
prostate. While in the transition zone the adenomatous hyper-
plasia interfered with cancer detection by PET, the quantita-
tive analysis tool performed well for cancer detection in the
peripheral zone.
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Introduction
Prostate cancer is one of the four most prevalent cancers
together with breast, colon and lung cancers in both the US
and Europe [1, 2]. In the year 2012, 241,740 new cases of
prostate cancer were estimated to have occurred in the US [1].
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Imaging of the prostate constitutes an increasing part in the
diagnostic work-up and therapy planning for both local and
disseminated disease. MRI is currently considered to be the
standard imaging modality for evaluating prostate cancer. T2-
weighted sequences are used to image the precise anatomy of
the normal and tumoral prostate, and the reported sensitivities
and specificities of MRI in the detection of prostate cancer
vary widely (47.8 – 88.2% and 44.3 – 81%, respectively) [3].
Imaging prostate cancer remains challenging and
multiparametric MRI with spectroscopy, diffusion-weighted
imaging, and dynamic contrast-enhanced MRI, has gained
acceptance to complement T2-weighted MRI for prostate
cancer detection and grading [4, 5].
PETwith 11C-labelled and 18F-labelled choline derivatives
has been used successfully for investigating rising prostate-
specific antigen (PSA) after prostatectomy [6–9], and for
initial staging before surgery [10–14] and radiation therapy.
The routine use of PET/CT for prostate cancer detection is still
controversial due to the technical limitations of PET (limited
spatial resolution and partial volume effect) and to limited
diagnostic accuracy of the tracer [15, 16]. However, none of
the previous studies used the “zonal” anatomy of the prostate
because the CT images did not allow adequate differentiation
of the peripheral zone (PZ) and transition zone (TZ). It is well
established that metabolic activity as assessed by PET over-
laps between TZ hyperplasia and cancer. Hence, the question
arose as to whether associating metabolic data with a high-
resolution technique such as MRI might potentially enhance
accuracy in prostate cancer imaging. Preliminary studies using
both modalities separately have provided inconsistent results
that could be explained in part by the difficulty in achieving
accurate registration of the PET and MR images [17, 18]. To
address this issue, hybrid PET/MRI systems have been de-
signed to allow PET and MRI acquisitions during a single
examination with a common patient position. We report here
the first results of 18F-fluorocholine PET/MRI of prostate
cancer in terms of examination feasibility and diagnostic
accuracy. The analysis was focused on the prostatic gland
and compared the diagnostic performance of combined PET/
MRI with that of multiparametric MRI alone.
Materials and methods
Patients
All consecutive patients scheduled for radical prostatectomy
as well as combined PET and MRI examination between
February 2010 and October 2011 were selected. The study
protocol was approved by the Institutional Review Board of
the GenevaUniversity Hospitals. All patients providedwritten
informed consent to the use of 18F-fluorocholine as an unreg-
istered radiopharmaceutical that was authorized for each
patient by the Swiss federal authorities (Swissmedic and Fed-
eral Office of Public Health, Section of Radioprotection).
The PET/MRI hybrid system
All PET/MRI scans were performed on a whole-body hybrid
PET/MRI system (Philips Ingenuity, Philips Healthcare,
Cleveland, OH) which provides a solution to previously de-
scribed technical issues in combining MR findings with PET
data [19]. The PET part of the hybrid system, a Philips Gemini
time-of-flight PET scanner, was combined with a Philips
Achieva 3.0-T X-series MRI scanner. The MRI-based attenu-
ation correction procedure has recently been described [20].
The PETandMRI scanners are separated by 4.2 m and located
on each side of a rotating table allowing the patient to be
moved sequentially from one scanner to the other. Alignment
between the MR and PET scanner was periodically calibrated
by the service engineering team. A dedicated phantom con-
taining six 22Na point sources spatially distributed in the three
spatial directions was used to verify that the distance between
the centroids of the point sources seen in MR and PET images
was less than 1 mm.
PET acquisition
The radiotracer doses were obtained from a commercial pro-
vider (Advanced Accelerator Applications, Saint-Genis-
Pouilly, France). Patients were requested to void before the
start of imaging. Patients underwent a continuous list-mode
PET acquisition of the pelvis over 10 min which was started
immediately after injection of 300MBq (8.11 µCi). Following
the list-mode acquisition, a standard whole-body PET study
was performed from the mid-thigh to the skull with seven or
eight bed positions of 4 min each depending on patient size
and weight according to the Steiner protocol [6]. The
sinogram data were corrected for dead time, decay and photon
attenuation, and were reconstructed on a 256×256matrix with
4-mm slice thickness. Image reconstruction followed a fully
three-dimensional maximum-likelihood ordered-subsets ex-
pectation maximum algorithm incorporating random and scat-
ter correction with two iterations and 28 subsets. The final in-
plane full-width at half-maximum of the system was 6 mm.
The whole-body MRI scan was segmented and used to create
an attenuation map to correct the PET images. In PET/MRI,
attenuation correction is less straightforward than in PET/CT
where the CT scan can be directly converted to an electronic
density map. Since MRI depicts proton density, weighted by
T1 and T2 relaxation parameters, the attenuation map is
obtained by segmenting the whole-body T1-weighted MR
images into three compartments, air, lung and tissue, which
are each assigned a different attenuation factor [20].
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MRI acquisition
The MR acquisition was a two-step process. First, pelvic T2
turbo spin echo (T2 TSE) sequences were acquired with an
endorectal coil combined with an external cardiac six-array
coil in the sagittal and axial planes in a 2-D method with the
following parameters: TR 4,000 ms, TE 120 ms, number of
signal averages (NSA) 2, slice thickness 3 mm, echo train
length 20, matrix 328/290 for the sagittal acquisition and 432/
386 for the axial acquisition, and field of view (FOV) 22 cm.
The endorectal coil was then removed and the acquisitions
were continued with only the external cardiac six-array coil in
place. A diffusion sequence was acquired on the prostate (TR
3,644 ms, TE 66 ms, slice thickness 3 mm, NSA 4, FOV
200 mm, and matrix 88/79) with four b-values (0, 500, 1,000,
1,500 s/mm2). A 3-D pelvic acquisition was performed with a
3-D fast spin echo MR sequence with TR 2,000 ms, TE
243 ms, NSA 1, slice thickness 1 mm, matrix 392/448/125,
and FOV 390 mm. At this time an intravenous bolus of
0.1 mmol/kg gadoterate dimeglumine (Dotarem®), a para-
magnetic gadolinium-containing contrast agent, was adminis-
tered. Perfusion consisted of a multiframe 3-D T1-weighted
fat-saturated gradient echo MR sequence with TR 6.9 ms, TE
3.4 ms, matrix 192/189, FOV 210 mm, slice thickness 3 mm,
and acquisition time 5 min. Finally, the entire abdomen was
examined for lymph nodes in five batches of a 3-D gradient
echo T1-weighted fat-saturated MR sequence with TR 3 ms,
TE 1.4 ms, matrix 228/227, FOV 375 mm, 30 slices, and slice
thickness 6 mm. Before injection of the contrast agent, the
whole-body attenuation correction axial fast field echo MR
sequence was acquired with the body coil from head to thighs
with TR 4.1 ms, TE 2.3 ms, slice thickness 6 mm, matrix 200/
200, and FOV 600 mm. The duration of the whole examina-
tion was assessed with the archiving system providing the
time of acquisition for each sequence.
Data processing
Postprocessing was applied to the MRI acquisitions to obtain
apparent diffusion coefficient (ADC) and pharmacokinetic
maps. ADC maps were obtained from monoexponential
fitting of the diffusion weighted sequences at b 0, 500, 1,000
and 1,500 s/mm2 with the Osirix plugin ADCmap version 1.5.
Volume transfer constants (Ktrans) and extravascular extracel-
lular volume fractions (ve) were calculated from the dynamic
contrast enhanced MRI scans using an extended Kety model
(a single-compartment model with extravascular correction)
and a predefined arterial input function [21]. This function
was taken from the literature based on data published by Fritz-
Hansen et al. [22]. All fitting was performed using an in-house
routine based on the R package dcemriS4, a package for
medical image analysis developed by Whitcher and Schmid
to perform voxel-wise quantitative analysis of dynamic
contrast-enhanced MRI scans (available from http://www.r-
project.org) [23, 24]. Before generating the pharmacokinetic
maps, data were converted to concentration values according
to the equation C(t)=(1/R1 × T10) * (S(t) − S(0))/S(0), where
R1 is the in vivo relaxivity at 3.5 L·mmol−1·s−1 [25], T10 is the
T1 of the prostatic tissue at 3 T before contrast agent injection,
set to a value at 1,597 ms obtained from published data [26];
S(t) is the voxel signal as a function of time, and S(0) is the
average of the baseline signal images. The procedure
generating the pharmacokinetic maps was then applied. The
fitting results must converge and ve must be included between
0 and 1 with respect to its significance.
PET/MRI analysis and parameters measurement
All PET and MRI images were analysed with dedicated soft-
ware (OsirixMD; Pixmeo SARL, Bernex, Switzerland). The
endorectal T2 sequences, diffusionmaps and pharmacokinetic
maps were interpreted in consensus by two radiologists
blinded to the PET results and the clinical data. The different
sequences in all patients were analysed independently in a
random order. The whole-body PET scans corrected for atten-
uation merged with the T2 sequences were interpreted by a
nuclear medicine physician experienced in prostate imaging
unaware of the other MRI results and the clinical data.
The analyses were performed using an eight-segment sub-
division of the prostate. For the PZ, the subdivision included
three levels: the base, the midgland, and the apex on both the
right and left sides. For the TZ, the subdivision included the
right or left side without level subdivision (Fig. 1). For each
sequence, a quantitative parameter was measured in all the
segments of the prostate by drawing freehand a region of
interest (ROI) either in a suspected lesion or in the background
activity within the segment if no lesion was detected. When a
tumoral lesion involved several segments, the measurement
was performed inside the main part of the lesion. In affected
adjacent segments, additional lesions were measured only if
clearly separated from the first one or if more than 50% of the
segment was involved; otherwise the measurements were
made in the background activity. One parameter was mea-
sured for each sequence. For the T2-weighted sequences, the
intensity was reported for the axial sections. A normalized T2
(nT2) was obtained using the signal of a normal hyperintense
T2 prostate region in the PZ. The diffusion-weighted se-
quences and dynamic contrast-enhanced imaging provided
the ADC and the pharmacokinetic parameters, Ktrans and ve,
from the corresponding colour-coded map. Maximum SUV
values (SUVmax) of the PET scans were obtained from the
whole-body acquisitions after attenuation correction and a
freehand ROI had been drawn in the axial plane after fusion
of the PET images with pelvic 3-D T2 sequences to ensure the
correct anatomical position of the ROI in the different pros-
tatic segments.
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Histopathological analysis
After radical prostatectomy, each specimen was fixed in 4 %
buffered formalin for at least 24 h. The prostate glands were
cut into axial sections from base to apex in a plane perpendic-
ular to the long axis of the prostate that was also used as
reference for the axial plane in the PETand MR imaging [16].
Sections were approximately 4 mm thick. The number of
sections varied between four and seven depending on the
dimensions of the prostatectomy specimen. Macroscopic pic-
tures of each section were taken. Whole-mount sections were
then completely embedded in paraffin blocks. Extra large
glass slides were prepared, stained with haematoxylin-eosin
and evaluated for the presence and grade of cancer. Foci of
cancer were marked on each slide using a fine indelible
marker pen. The pathologist was kept unaware of the imaging
findings. For exact correlation of histopathology with the
imaging findings, the slides from the whole-mount step sec-
tions were digitized using a commercially available scanner;
slides were arranged from the base to the apex according to the
radiological images. The histological slides were analysed to
establish the gold standard. The same eight-segment subdivi-
sion of the prostate previously defined for the imaging data
was applied to these sections. Each of the eight segments was
assigned as normal or tumoral. For large tumours invading
two or more segments, the segment with the largest part of the
tumour was always considered tumoral. Contiguous segments
were considered tumoral when the tumour extended to more
than 50 % of the section area according to the same method
used for imaging assessment. Microfoci of tumour of less than
3 mm in diameter were not considered. Sectors with
intraepithelial neoplasia (PIN) were scored as normal. Prostate
segments were then compared between imaging and
histology.
Statistical analysis
The PETandMRI parameters were compared between normal
and tumoral values using the nonparametric Wilcoxon rank
sum test. For each parameter, a receiver operating character-
istic (ROC) curve was computed and the area under the curve
(AUC) measured. The performance of the parameters was
compared using a unilateral test based on bootstrapping for
statistical significance. The cut-off values were obtained from
the ROC curves as the points closest to the top-left corner. In
order to compare the performance of MR examination alone
(MRmodel), combination ofMR and PET (PETMRmodel), a
multivariate logistic regression model was built after stepwise
parameter selection based on Akaike’s information criterion
(AIC) which was used as a measure of the fit of the model. A
stepwise procedure was applied by sequentially adding the
parameters to achieve the best model (a parameter was added
to the model if the AIC obtained was lower). For the selected
parameters, the generalized estimating equations (GEE) were
used to compute the correct p values for the regression coef-
ficients in order to consider the clustered measured data within
each patient. The AUC for each model was calculated and
compared using a unilateral test of significance based on
Delong’s method. The sensitivity and specificity of each mod-
el were obtained from the ROC curves as the points closest to
the top-left corner. Using all normal and tumoral segments,
correlations between pairs of imaging parameters were exam-
ined with Spearman's correlation coefficient. The effect of
Gleason score on the parameters was assessed using one-
way analysis of variance. All statistical analyses were per-
formed using the R statistical environment version 2.15 (avail-
able from http://www.r-project.org/). The package geepack
was used to perform the GEE and the package pROC to
compute the ROC curves [27]. For all the tests, the
significance level was fixed at 0.05.
Results
Patients and histological results
A total of 26 patients underwent radical prostatectomy after a
PET/MRI examination. Although all the examinations were of
Fig. 1 Prostate division into eight segments respecting the zonal anato-
my. For the peripheral zone (light grey), the prostate was separated into
the left and right side in the base (segments 1 and 2), the midgland
(segments 3 and 4) and the apex (segments 5 and 6). For the transition
zone (dark grey), the prostate was divided into two segments including
the right and left side without level subdivision (segments 7 and 8)
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diagnostic quality, three patients were excluded from the study
because of incomplete data due to refusal of the endorectal
coil (two patients) or artefacts induced by a hip prosthesis (one
patient). Thus, 23 patients were enrolled in the study (median
age 64 years, range 47 – 75 years). In the resected prostate
glands, Gleason grade 3+4 was predominant (9 of 23 patients,
39 %) followed by grade 4+3 (6, 26 %), grade 4+5 (6, 26 %)
and grade 3+3 (2, 8 %). There was microscopic evidence of
high-grade PIN (HGPIN) in 65% of patients (15 of 23). In one
patient, there was a significant amount of HGPIN in the
prostatic gland with several confluent foci of HGPIN measur-
ing up to 1 cm in largest diameter, distant and separated from
the adenocarcinoma location. In all other patients, HGPIN
was either admixed with the adenocarcinoma as a minor
component of the tumour (less than 10 %), or present as
microfoci elsewhere in the prostate. Cancer was present in
the PZ in 17of 23 patients (74 %) and in the TZ in 11 patients
(48 %), while 6 patients (26 %) had tumour in both zones. By
histomorphometric analysis, tumour volume (median 3.2 cm3,
range 0.23 – 29.1 cm3) and prostate volume (median
41.1 cm3; range 23.6 – 88.7 cm3) were assessed in each
patient. A total of 184 prostatic segments were analysed in
the 23 patients, with 46 segments in the TZ and 138 in the PZ.
Among all the 184 segments, 53 (29 %) were positive for
tumour according to our histological gold standard with 41 of
138 (30 %) in the PZ and 12 of 46 (26 %) in the TZ.
Image quality
All patients underwent the complete examination including
both PETandMRI acquisitions in a single session without any
noticeable discomfort and with median duration of 121 min
(range 67 – 167 min). Both PET and MRI examinations were
of diagnostic quality without any degradation related to the
hybrid system. A representative example of prostate PET/
MRI demonstrating image quality is shown in Fig. 2; the
video of the same case is available in the Electronic supple-
mentary material and shows the lesion in the left apex of the
PZ (indicated by an arrow) and the metabolic activity of the
TZ (indicated by asterisks). In addition to the phantom regis-
tration procedure periodically performed, the quality of the
registration between the twomodalities was assessed by visual
analysis of the merged images obtained from theMR and PET
acquisitions. Use of the endorectal T2-weighted images and
the whole-body PET images for registration was not possible
due to the elastic deformation and anterior shift of the prostate
induced by the inflated coil balloon. The 3-D Vista MR
images (acquired without the endorectal coil) and whole-
body PET registration procedure was excellent and was very
easy without the need for elastic deformation correction.
Using the pelvic bone as a landmark, considered a fixed
structure not mobilized by breathing, digestive motility or
bladder filling, a slight (1 – 3.5 mm) translation in the axial
plane in seven patients (30 %) and a moderate translation
(3.5 – 7 mm) in eight patients (35 %) with no shift in the z-
axis were manually corrected.
PET and MRI univariate analysis
Statistics regarding the whole prostate, the PZ and the TZ are
summarized in Table 1 with the corresponding AUCs of the
ROCs curve in Table 2. For the whole prostate (PZ+TZ), the
best AUC was obtained with SUVmax and ADC, followed by
nT2, Ktrans and ve. No significant difference was observed
between the SUVmax AUC and the ADC AUC (p=0.45).
However, the SUVmax AUC significantly differed from the
nT2 (p=0.03), Ktrans (p<0.001) and ve (p<0.001) AUCs.
From the ROC curves, the best cut-off values for the diagnos-
tic accuracy of ADC and SUVmax were, respectively, 1.075
×10−3 mm2/s and 3.044. The PZ demonstrated the same
behaviour as the whole prostate with the best AUC obtained
with SUVmax and ADC (Fig. 3). In the TZ, such a relationship
was not present. SUVmax and K
trans even showed an AUC
lower than 0.5 as a result of the presence of benign
hypervascular and hypermetabolic hyperplastic nodules with
SUVmax andK
trans values higher than tumoral values (Table 1).
As a consequence, it was not possible to compute an optimal
threshold for the TZ SUVmax.
MR versus PET/MRI multivariate analysis
The data in the multivariate analysis are shown in the Tables 3
and 4. For the whole prostate gland, the statistical analysis
using the stepwise procedure in the logistic regression showed
that ADC, ve and nT2 were the best parameters for the MR-
only model (the AICs were 223, 191, 185, 184.5 and 184.8 for
the starting model, model+ADC, model ADC+ve, model
ADC+ve+nT2 and model ADC+ve+nT2+K
trans, respective-
ly), and that ADC, ve and SUVmax were the best parameters
for the PETMRmodel (the AICs were 223, 191, 179, 173, 174
and 175 for the starting model, model+ADC, model ADC+
SUVmax, model ADC+SUVmax+ ve, model ADC+
SUVmax+ve+K
trans and model ADC+SUVmax+ve+nT2,
respectively). Fitting both models using the GEE showed
significant regression coefficients for ADC, ve and SUVmax.
However, the AUC of the PETMRmodel ROC curve was not
significantly improved by the addition of PET in comparison
with the MR model.
For the TZ, the same analysis showed that ve and ADC
were the best parameters for the MR only model (the AICs
were 54.8, 53, 50, 51.9 and 52 for the starting model, model+
ADC, model ADC+ve, model ADC+ve+K
trans and model
ADC+ve+nT2, respectively ), with significant coefficients
after fitting the model by GEE. However, in the PETMR
model, SUVmax was not selected by the stepwise procedure,
and the PETMR model remained the same as the MR model
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Fig. 2 18F-Fluorocholine prostate PET/MR imaging in a 71-year-old
patient (PSA 6.26 ng/ml, Gleason score 7): a T2-weighted axial image
with endorectal coil, bADCmap, c coregistered image from the MR 3-D
T2-weighted axial and colour-coded PET acquisitions, d H&E-stained
histology section. In the PZ of the left apex, a focus is well-defined on the
T2-weighted image and the ADC map and is seen as a hypermetabolic
focus on the coregistered image (short arrows). This lesion was well
depicted by all modalities with a strong correlation between the PET and
MRI data and confirmed by histology. However, in the right apex, another
suspicious lesion is apparent on the T2-weighted image and the ADC
map (long arrows), but no right apical lesion was visible on the PET
acquisition, failing to confirm the MR-based suspicion. The correspond-
ing histology section shows normal tissue at this position
Table 1 Imaging parameters
Zone Parameter Normal region, median (range) Tumoral region, median (range) p valuea
PZ+TZ nT2 0.7372 (0.3372 – 1.116) 0.5579 (0.2865 – 1.005) 8.686 × 10−5
ADC (× 10−3 mm2/s) 1.241 (0.484 – 1.829) 0.994 (0.448 – 1.481) 5.783 × 10−8
Ktrans (1/min) 0.0693 (0.0264 – 0.195) 0.0909 (0.0363 – 0.191) 0.01844
ve 0.1759 (0.0426 – 0.423) 0.1714 (0.0787 – 0.304) 0.545
SUVmax 2.3 (1.2 – 6.5) 3.711 (1.234 – 9.4) 2.792 × 10
−8
TZ nT2 0.534 (0.437 – 0.766) 0.527 (0.35 – 0.739) 0.7766
ADC (× 10−3 mm2/s) 1.127 (0.540 – 1.343) 0.975 (0.5858 – 1.298) 0.1381
Ktrans (1/min) 0.123 (0.0268 – 0.195) 0.096 (0.0608 – 0.191) 0.1751
ve 0.215 (0.116 – 0.35) 0.171 (0.0952 – 0.304) 0.1018
SUVmax 4.35 (2.02 – 6.5) 3.66 (2.54 – 6.7) 0.4604
PZ nT2 0.83 (0.337 – 1.12) 0.583 (0.286 – 1.01) 3.033 × 10−6
ADC (× 10−3 mm2/s) 1.282 (0.4841 – 1.829) 0.9946 (0.4483 – 1.481) 4.388 × 10−8
Ktrans (1/min) 0.0619 (0.0264 – 0.146) 0.0899 (0.0363 – 0.161) 0.000435
ve 0.165 (0.0426 – 0.423) 0.171 (0.0787 – 0.302) 0.6148
SUVmax 2.1 (1.2 – 5.5) 3.8 (1.23 – 9.4) 3.647 × 10
−11
a Nonparametric Wilcoxon rank sum test
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without change in the AUC of the ROC curve (the AICs were
54.8, 53, 50, 51.2, 51.9 and 52 for the starting model, model+
ADC, model ADC+ve, model ADC+ve+SUVmax, model
ADC+ve+K
trans and model ADC+ve+nT2, respectively).
For the PZ, the selected parameters for the MRmodel were
the nT2, ADC, Ktrans and ve with significant regression coef-
ficients for the three last (the AICs were 170, 138, 134, 128
and 127 for the starting model, model+ADC, model ADC+
Ktrans, model ADC+Ktrans+ve and model ADC+K
trans+ve+
nT2, respectively). For the PETMRmodel, only the ADC and
SUVmax parameters were retained as the covariates of the
model with significant p values after fitting by GEE (the AICs
were 170, 110, 102, 104, 104 and 104 for the starting model,
model+SUVmax, model SUVmax+ADC, model SUVmax+
ADC+nT2, model SUVmax+ADC+Ktrans and model
SUVmax+ADC+ve, respectively). In the PZ, the addition of
PET led to a significant improvement in the AUCs of the ROC
curves. As inferred from the ROC curves and as shown in
Table 4, the best sensitivity and specificity were 76 % and
79% for theMRmodel versus 78% and 88% for the PETMR
model (Fig. 4). The specificities for both the MR and PETMR
models were highest in the PZ and lowest in the TZ (Table 4).
Table 5 shows the sensitivity, specificity and accuracy of
the two best-performing parameters (ADC and SUVmax) as
well as of the MR and PETMR examinations. In terms of
accuracy and specificity, SUVmax and PETMR performed
better in the PZ alone than in the whole prostate. The TZ is a
predilection site for benign pathology such as adenomatous
hyperplasia that may cause false-positive leading to a decrease
in PET specificity. However, the false-negative rate and sen-
sitivity were not improved in the PZ by comparison to the
whole prostate as the detection of tumoral foci was limited by
low tumoral avidity or by PET spatial resolution and the
related partial volume effects.
Correlation among imaging parameters and analysis
of the Gleason score
The correlations among the imaging parameters for all pros-
tatic segments are shown in Table 6. All coefficients in
Table 2 AUC of the ROC curve for each parameter
Zone Parameter AUC 95 % confidence interval Threshold Sensitivity (%) Specificity (%)
PZ+TZ nT2 0.685 0.6023 – 0.7677
ADC (× 10−3 mm2/s) 0.756 0.679 – 0.832 1.075 58.4 78.6
Ktrans (1/min) 0.611 0.522 – 0.7
ve 0.529 0.438 – 0.619
SUVmax 0.762 0.685 – 0.838 3.044 75.5 73.3
TZ nT2 0.529 0.304 – 0.755
ADC (× 10−3 mm2/s) 0.647 0.439 – 0.855 0.899 50.0 91.2
Ktrans (1/min) 0.365 (<0.5) 0.164 – 0.567
ve 0.662 0.462 – 0.861
SUVmax 0.426 (<0.5) 0.219 – 0.634 NA NA NA
PZ nT2 0.752 0.662 – 0.842
ADC (× 10−3 mm2/s) 0.796 0.715 – 0.876 1.190 73.2 70.1
Ktrans (1/min) 0.69 0.586 – 0.794
ve 0.473 (<0.5) 0.369 – 0.576
SUVmax 0.857 0.774 – 0.94 2.882 75.6 91.8
NA not applicable
Fig. 3 ROC curves for each imaging parameter obtained in the PZ of the
prostate. The diagnostic accuracy was measured in terms of the AUC
shown in the bottom-right of the figure in decreasing order. The best
parameter corresponds to SUVmax with the highest AUC
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absolute values were lower than 0.6 with a coefficient of
−0.425 between the SUVmax and ADC. Three levels of
Gleason score were considered: 3+4 (26 positive segments),
4+3 (positive segments) and 4+5 (18 positive segments).
Gleason scores 4+4 and 3+3 were not considered (1 or 2
positive segments). The Gleason score had a significant effect
on ADC (p=0.037) and nT2 (p=0.037). The other parameters
did not differ significantly (SUVmax p=0.2032, K
trans p=
0.505, ve p=0.9231)
Discussion
This study demonstrated the feasibility of hybrid PET/MRI
scans in prostate cancer detection by the high rate of success-
ful examinations. All patients tolerated well the examination
time with a median of 121 min. The images were all of
diagnostic quality even in the three patients excluded from
the study because of missing imaging series preventing their
inclusion in the statistical analysis. In particular, we did not
notice any image degradation of either the PET and MR
images that could have been caused by the closeness of the
PET and the MR systems in the same room [19]. We also
investigated the value of hybrid PET/MRI in prostate cancer
detection. The separate results obtained from the PET or MRI
data alone were in agreement with those in the literature. For
the whole prostate, the MR parameter with the highest
diagnostic efficiency was ADC, followed by nT2, Ktrans and
finally ve, in agreement with the findings of previous studies
[28, 29]. The ADC values in the PZ and in the TZ were
different, as previously reported [30]. In our study, the AUCs
from the ADC curves were 0.796 for the PZ and 0.647 for the
TZ; these values are lower than those found in a previous
study byKitajima et al. (AUC 0.937 in the PZ and 0.889 in the
TZ with b-values of 0 – 2,000 s/mm2) [31]. This difference
can be explained by a difference in the methodology. In our
study, microfoci were considered <3 mm versus 5 mm in the
study by Kitajima et al. and the ROIs for the measurements
were placed blinded to the histological slides, in contrast to the
study by Kitajima et al. The PET results were also in agree-
ment with those of previously published studies. Our SUVmax
cut-off of 3.044 found to give the best accuracy of PET was
consistent with the value of 2.7 reported previously for 11C-
Table 3 Regression coefficients in the MR and PETMR multivariate logistic models (fitted using GEE)
Zone Model nT2 ADC Ktrans ve SUVmax
PZ+TZ MR −1.75 (p=0.0885) −4.14 (p=0.0024) –a −9.55 (p=0.0013) Not included
PETMR –a −3.97 (p=0.00187) –a −9.80291 (p=0.00041) 0.45033 (p=0.00054)
TZ MR –a −4.19 (p=0.00229) –a −15.14549 (p=0.00734) Not included
PETMR –a −4.19 (p=0.00229) –a −15.14549 (p=0.00734) –a
PZ MR −2.39 (p=0.0378) −3.47 (p=0.0255) 30.51 (p=0.0111) −11.68 (p=0.0013) Not included
PETMR –a −3.21 (p=0.02166) –a –a 1.30094 (p=0.00028)
a Not selected by stepwise forward procedure for the MR model or the PETMR model
Table 4 Diagnostic accuracy of the MR and PETMR multivariate logis-
tic models. The p values comparing the AUCs of the two models were
obtained from the parameters shown in Table 5. The diagnostic accuracies
were deduced from the ROC curve as the points closest to the top-left
corner
Zone Model AUC p value Sensitivity (%) Specificity (%)
PZ+TZ MR 0.795 0.1021 66.0 85.5
PETMR 0.817 79.2 69.5
TZ MR 0.75 0.5 83.3 58.8
PETMR 0.75 83.3 58.8
PZ MR 0.84 0.0402 75.6 79.4
PETMR 0.893 78.0 87.6
Fig. 4 ROC curves for the MR model and PETMR model for the PZ.
The two points indicated by the arrows correspond to the best cut-off
values and are the points closest to the top-left corner. The PETMRmodel
curve is to the left of the MRmodel curve indicating diagnostic improve-
ment achieved by combining MR imaging with PET. The AUC for each
curve is shown in the bottom-right (Sp specificity, Se sensitivity)
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choline [18]. Finally, in a study in 33 patients using biopsy as
the gold standard, Jambor et al. found an improvement in
specificity when using PET/CT and MRI registered data
[17]. The results of that study converge towards our results
for the PZ of the prostate showing an improvement in the
ROC curve for the PZ.
The potential of hybrid PET/MRI in prostate cancer detec-
tion was investigated by considering the combined informa-
tion from both PET and MRI data. Hybrid PET/MRI allowed
optimal conditions for the registration of the two modalities to
be obtained. In addition to the absence of radiation associated
with CT, hybrid PET/MRI allowed reliable acquisition of both
PET and MRI data in a single session to ease patient manage-
ment. In our study, registration of PET and MR could be
performed accurately under stable conditions: pelvic tilt did
not change during the examination since the patient did not
need to move from one scanner table to another, and rectal
filling was equal thus avoiding modification of the prostate
position as a result of differences in distension. We also asked
the patients to void before the examination tominimize chang-
es in bladder volume. These factors avoided elastic and non-
linear image deformation and allowed optimal conditions for
image registration and accurate analysis of the anatomical
zones of the prostate. Regarding the literature, previous stud-
ies have been performed using two separate imaging sessions
for PET/CTandMRI, and the conditions for registration could
not be as close as those obtained in a single session [17, 18,
32]. In a large study including 49 patients scheduled for
radical prostatectomy Van den Bergh et al. compared the
results of 11C-choline PET/CT and T2-weighted MRI of the
prostate [18] and concluded that the value of 11C-choline PET/
CT in addition to T2-weighted MRI was limited. In our study,
the addition of PET toMRI led to an improvement in the ROC
curve in the PZ. The main factor that could explain these
different results is that in the study by Van den Bergh et al.
PET/CT and MRI were registered using a rigid body algo-
rithm that poorly corrected for deformation of the prostate
resulting from differences in pelvic position during the two
imaging sessions.
As there is an overlap in SUVmax between TZ hyperplasia
and cancer [33], we strongly believe that different analyses
should be applied to PET data originating from the PZ and
from the TZ. The results presented in Table 5 emphasize the
importance of respecting prostatic zonal anatomy in the anal-
ysis of a hypermetabolic focus. The PZ thickness may be
reduced in patients with benign prostate hyperplasia and
may result in false-positive findings on PET/CT examination
in which zonal differentiation is not possible due to poor soft
tissue contrast on CT images. For this reason, there is an
advantage in the use of hybrid PET/MRI compared with
PET/CT. In our experience, fusion of PET and MR Vista 3-
D data improved ROI positioning within the PZ and the TZ
allowing an accurate metabolic value to be obtained. Previous
studies were performed without anatomical zone delineation
of the prostate but with arbitrary regional divisions that did not
consider the metabolic and functional differences within the
prostate. For example, in the large study by Van den Bergh
et al. including 49 patients, an octant division of the prostate
was used without differentiating the TZ and the PZ [18]. Such
analysis may not be able to show the additional value of PET
with MRI.
While in this study the MR regression model showed that
all functional parameters (i.e. ADC, Ktrans and ve) provided
diagnostic accuracy in the PZ, the best-performing parameters
in the PETMR model were SUVmax and ADC. The parameter
selection procedure in the logistic regression model demon-
strated that these two parameters were the most relevant.
However, our current study did not show a strong correlation
between ADC and SUVmax (correlation coefficient −0.425),
indicating that these two parameters are independent
Table 5 Sensitivity, specificity and accuracy of the two best-performing
parameters and for the MR and PETMR examinations. Considering the
peripheral zone alone in contrast with the whole prostate, the addition of
PET improves the performance mostly in terms of accuracy and specific-
ity, showing the value of segmenting the prostate according to the zonal
anatomy
Whole prostate Peripheral zone
Sensitivity (%) Specificity (%) Accuracy (%) Sensitivity (%) Specificity (%) Accuracy (%)
ADC 58 79 69 73 70 72
SUVmax 76 73 75 76 92 84
MR 66 86 76 76 79 78
PETMR 79 70 75 78 88 83
Table 6 Spearman's rank correlation matrix for the imaging parameters
nT2 ADC Ktrans ve SUVmax
nT2 1 0.563 −0.354 −0.192 −0.507
ADC 1 −0.394 −0.319 −0.425
Ktrans 1 0.541 0.572
ve 1 0.119
SUVmax 1
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biomarkers in prostate cancer. Correlation with Gleason
scores demonstrated the different behaviour of these two
parameters. While in our study the Gleason score significantly
affected ADC (p=0.0027), SUVmax did not change signifi-
cantly (p=0.355) as previously demonstrated [34, 35]. 18F-
Choline uptake provides metabolic information based on
incorporation of phosphatidyl choline in proliferating
cell membrane while ADC is a functional biomarker
based on the assessment of random (brownian) motion
of extracellular water molecules. Also, the relationship
between ADC and Gleason score [36–38] and the rela-
tionship between perfusion parameters and microvascu-
lature are well established [39], whereas the correlation
between ADC and cellularity remains controversial [40,
41]. In addition, our study demonstrated the role of ve.
As a single parameter, the information it provided was
of little value with the AUC of the ROC curve of only
0.529. However, the parameter helped classify lesions
when used in combination with other parameters and
was a significant covariate in the logistic regression.
This is an interesting observation as the importance of
ve is still the subject of debate in the literature [28, 42].
In the multivariate logistic regression, the parameter
showed a negative coefficient; this is concordant with
the significance of the parameter as a measure of the
extravascular extracellular space fractional volume and
thus “as marker of cellular density” [43].
The study was performed using a 3-T PET/MRI
system allowing sequential acquisition. The system was
designed as an arrangement of separate PET and MR
scanners placed in the same room and using a common
rotating table. Another commercially available concept
places both scanners in separate rooms; a mobile table
transfers the patient keeping the same position to allow
registration between the two modalities. A third ap-
proach combines PET and MR systems in a unique
gantry. In theory, our results could be extrapolated to
such PET/MRI systems allowing simultaneous acquisi-
tions of both modalities. However, further studies with
this hybrid system should be performed to better eval-
uate the performance of such integrated technology.
Software coregistration could provide an alternative to
multimodal analysis with rigid or nonrigid fusion algo-
rithms [44].
Our study questions the role of PET/MRI in the current
strategy for prostate cancer detection and staging. Hybrid
examination could be used as a second-line imaging method
in patients with elevated PSAwith negative tumoral findings
on repeated biopsies and MR examinations. The PET imaging
may lead to improved cancer detection in the PZ when MRI
alone does not allow a reliable analysis. Such a situation may
be caused by biopsy-induced changes and haemorrhage [45].
Considering the absence of a significant relationship between
the Gleason score and the uptake of 18F-fluorocholine, PET/
MRI may also be of value in the evaluation of well-
differentiated tumours. This potential needs further investiga-
tion in the setting of patient management by active surveil-
lance. Furthermore, the value of this hybrid imaging for
tumour delineation in planning of dose painting radiation
therapy could be assessed [46].
Study limitations
While the reading of the MRI and PET scans was performed
blinded and in separate sessions, the reader of PET data had
access to the T2-weighted MRI sequence data to differentiate
TZ from PZ. Therefore, it was not possible to exclude a bias in
the PET data analysis that could have been introduced by the
visualization of the T2-weighted sequence data. However,
ROC analysis clearly demonstrated that even with this possi-
ble bias, the PET data added new information and improved
the accuracy of prostate cancer detection in the PZ. Quantita-
tive PET data also depend on the accuracy of tissue attenua-
tion correction. The method used in our system relied on
computer segmentation of different tissue types particularly
soft tissue and air-filled structures, assigning a standard atten-
uation coefficient to the soft tissues. In the current setting
bones are not identified and can be assumed to have the same
attenuation coefficient as soft tissue. Some preliminary data
and simulations showed that this approximation can lead to
variation in body SUVs of up to about 5 %, and especially in
bony lesion SUVs of up to 31 % [47]. While this variability
may be important in bone assessment, these errors are still
acceptable for prostate analysis. Furthermore, accuracy will be
increased when work currently in progress developing algo-
rithms considering bone are available for attenuation
correction.
Conclusion
Acquisition of a whole-body 18F-fluorocholine PET/MRI
scan on a hybrid system in a single session with a
multiparametric MRI of the prostate was feasible without
any compromise in image quality. The distinction between
the PZ and TZ proved to be of the utmost importance in
prostate analysis. The registration of the PET data with the
anatomical T2-weighted MR sequence on the hybrid system
led to to precise localization of hypermetabolic foci. In the TZ,
adenomatous hyperplasia may lead to false-positive uptake in
18F-choline and the use of the PET/MRI did not lead to better
diagnostic accuracy than MR alone. In the PZ, quantitative
and anatomical assessment of hypermetabolic foci in the
prostate led to better performance of PET/MRI in detecting
prostate cancer than multiparametric MRI. ADC and the
SUVmax were not strongly correlated biomarkers, suggesting
that they provide complementary information. Furthermore,
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higher Gleason scores in tumour led to higher ADC but not to
higher SUVmax.
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